Nov 5, 7:32 AM ET
Collegium Pharmaceutical reported third-quarter 2026 product revenues of $216.3 million, up 3% from a year earlier, but GAAP diluted earnings per share fell to $0.60 from $0.84 and adjusted EBITDA fell 9% to $121.6 million. The company reaffirmed its full-year 2026 guidance and said it expects to complete a $50 million accelerated share repurchase before the end of the year.
- Product revenues, net were $216.3 million versus $209.4 million a year earlier; JORNAY PM net revenue rose 24% to $51.9 million.
- GAAP net income was $21.8 million, or $0.60 diluted EPS, compared with $31.5 million, or $0.84, in the third quarter of 2025.
- Adjusted EBITDA was $121.6 million, down from $133.0 million; full-year 2026 adjusted EBITDA guidance of $445 million to $470 million was reaffirmed.
- Pain portfolio net revenues fell 18% to $138.0 million, while AZSTARYS contributed $26.5 million in its first full quarter under Collegium ownership.
Read the filing on SEC.gov ↗
Oct 19, 4:05 PM ET
Collegium Pharmaceutical agreed on October 15, 2026 to settle all disputes with Grünenthal GmbH, including a patent infringement lawsuit over the Nucynta ER authorized generic. As part of the settlement, the company's license agreement with Grünenthal was terminated in its entirety, and the company made a $17 million payment, after which no further royalties are due under that license.
- Settlement agreement dated October 15, 2026 resolves all disputes, including the Nucynta Litigation filed in February 2026 in the District of New Jersey
- Collegium paid Grünenthal $17 million; the Grünenthal License terminated effective October 15, 2026
- No further royalties will be due under the Grünenthal License; Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the lawsuit
Read the filing on SEC.gov ↗
Aug 6, 7:33 AM ET
Collegium reported second-quarter 2026 product revenues of $199.9 million, up 6% from a year earlier, and a GAAP net loss of $15.1 million, compared with net income of $12.0 million a year earlier. The company completed its AZSTARYS acquisition in May, but lowered its full-year 2026 guidance for product revenues and adjusted EBITDA, citing lower-than-expected revenue from authorized generic versions of Nucynta and Nucynta ER.
- Q2 2026 product revenues, net of $199.9 million, up 6% year over year; JORNAY PM net revenue of $46.1 million, up 41%
- GAAP net loss of $15.1 million, or $(0.46) per share, versus GAAP net income of $12.0 million, or $0.38 per share, in Q2 2025
- Full-year 2026 product revenues, net guidance lowered to $825 million to $855 million from $865 million to $895 million; adjusted EBITDA guidance lowered to $445 million to $470 million from $475 million to $500 million
- AZSTARYS acquisition completed in May 2026 and generated $12.9 million in net revenue from May 12 to June 30, 2026; AZSTARYS 2026 revenue guidance raised to $65 million to $75 million
Read the filing on SEC.gov ↗
May 12, 7:43 AM ET
Collegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD medicine, on May 12, 2026, for approximately $650 million in cash, subject to customary adjustments. The company raised its 2026 product revenue and adjusted EBITDA guidance to include the acquisition, but its Chief Commercial Officer and Chief Medical Officer are both departing.
- Purchase price of approximately $650 million in cash, funded by about $350 million of existing cash and a $300 million delayed draw term loan, with up to $135 million more tied to future milestones
- 2026 Product Revenues, Net guidance raised to $865 million to $895 million from $805 million to $825 million
- 2026 Adjusted EBITDA guidance raised to $475 million to $500 million from $455 million to $475 million
- Chief Commercial Officer Scott Dreyer departs effective August 30, 2026; Chief Medical Officer Thomas Smith departs after a transition period
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.